Cargando…

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer

Background: Lung cancer is the leading cause of brain metastases (BM). The identification of driver oncogenes and matched targeted therapies has improved outcome in non-small cell lung cancer (NSCLC) patients; however, a better understanding of BM molecular biology is needed to further drive the pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomasini, Pascale, Serdjebi, Cindy, Khobta, Nataliya, Metellus, Philippe, Ouafik, L’Houcine, Nanni, Isabelle, Greillier, Laurent, Loundou, Anderson, Fina, Frederic, Mascaux, Celine, Barlesi, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187932/ https://www.ncbi.nlm.nih.gov/pubmed/27999344 http://dx.doi.org/10.3390/ijms17122132

Ejemplares similares

Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study
por: Tomasini, Pascale, et al.
Publicado: (2020)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Machine learning random forest for predicting oncosomatic variant NGS analysis
por: Pellegrino, Eric, et al.
Publicado: (2021)

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018)

Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity
por: Pellegrino, Eric, et al.
Publicado: (2023)

Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
por: Frankel, Diane, et al.
Publicado: (2023)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors
por: Fina, Frédéric, et al.
Publicado: (2016)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway
por: Tabouret, Emeline, et al.
Publicado: (2015)

Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples
por: Frankel, Diane, et al.
Publicado: (2022)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR
por: Macagno, Nicolas, et al.
Publicado: (2018)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
por: Ruppert, Anne-Marie, et al.
Publicado: (2020)

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors
por: Sigaud, Romain, et al.
Publicado: (2021)

Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study
por: Kembou Nzale, Samuel, et al.
Publicado: (2020)

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers
por: Lamy, Pierre-Jean, et al.
Publicado: (2011)

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017)

Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo
por: Nouguerède, Emilie, et al.
Publicado: (2013)

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
por: Jean, Fanny, et al.
Publicado: (2017)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling
por: Khalfaoui-Bendriss, Ghizlane, et al.
Publicado: (2015)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
por: Dahan, Laetitia, et al.
Publicado: (2011)

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
por: Benzekry, Sébastien, et al.
Publicado: (2021)

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
por: Tallet, Agnes V, et al.
Publicado: (2012)

Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis
por: Benyahia, Zohra, et al.
Publicado: (2022)

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
por: Mogenet, Alice, et al.
Publicado: (2021)

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
por: Bilous, M., et al.
Publicado: (2019)

TRPV2 Mediates Adrenomedullin Stimulation of Prostate and Urothelial Cancer Cell Adhesion, Migration and Invasion
por: Oulidi, Agathe, et al.
Publicado: (2013)

Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer
por: Tallet, Agnes V., et al.
Publicado: (2014)

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy
por: Vázquez, Ramiro, et al.
Publicado: (2021)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience
por: Blons, Hélène, et al.
Publicado: (2013)

Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion
por: Benyahia, Zohra, et al.
Publicado: (2017)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
por: Imbs, Diane‐Charlotte, et al.
Publicado: (2017)

Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status
por: Eyraud, Rémi, et al.
Publicado: (2023)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_d5a1uua0hrp144hhmp0u08a1kf